Last reviewed · How we verify
immunomodulatory treatment by rituximab
Rituximab works by binding to the CD20 antigen on the surface of B cells, leading to their depletion and subsequent immunomodulation.
Rituximab works by binding to the CD20 antigen on the surface of B cells, leading to their depletion and subsequent immunomodulation. Used for Non-Hodgkin lymphoma, Rheumatoid arthritis.
At a glance
| Generic name | immunomodulatory treatment by rituximab |
|---|---|
| Sponsor | University Hospital, Bordeaux |
| Drug class | Monoclonal antibody |
| Target | CD20 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
This results in a reduction in B cell count and function, which can help to alleviate symptoms and slow disease progression in conditions such as rheumatoid arthritis and non-Hodgkin lymphoma. Rituximab's mechanism of action is primarily through the depletion of B cells, but it may also have effects on other immune cells and cytokines.
Approved indications
- Non-Hodgkin lymphoma
- Rheumatoid arthritis
Common side effects
- Infusion reactions
- Infections
- Neutropenia
- Thrombocytopenia
- Anemia
Key clinical trials
- Prospective Evaluation of Diagnosis and Treatment of Patients With Autoimmune Cytopenias Including Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, and Chronic Idiopathic/Autoimmune Neutropenia
- Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy (PHASE2)
- Evaluation of the Efficacy of Immunomodulatory Therapy in Case of Psychiatric Disorders With Proven Dysimmunity. (PHASE3)
- Demyelinating Diseases of the Central Nervous System Registry for Patients With Traditional Chinese Medicine (DATE-TCM)
- Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia (PHASE1)
- Observational Study for Subjects With Pompe Disease Undergoing Immune Modulation Therapies
- Lupus Immunosuppressive/Immunomodulatory Therapy or Stem Cell Transplant (LIST) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: